Search
for

    Sort by

    Community Join

    840-870 / 1000+ results

      community The expected timeline for PP405 - Next update at AAD Annual Meeting in March 2026 ?

      in Treatment  30 upvotes 6 months ago
      A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

      community Thoughts on the future of pp405?

      in Research/Science  43 upvotes 7 months ago
      PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

      community Pyrilutamide/KX-826 where to buy? Effectiveness? Sides?

      in Research/Science  14 upvotes 3 years ago
      User seeks KX-826 anti-androgen product and asks for purchase suggestions and experiences. Dave-8D recommends buying powder from the same website and making a topical solution, mentioning possible high dosage from Minoxidil max causing side effects.

      community Anyone only on RU or Pyrilutamide?

      in Research/Science 1 year ago
      The conversation discusses using RU58841 or Pyrilutamide for hair loss, with some users suggesting switching to more proven treatments like oral or topical finasteride. One user reports no progress with RU58841, finasteride, and minoxidil, and mentions experiencing regression.

      community Doctors won't let me try bicalutamide or fin

      in Female  6 upvotes 5 years ago
      Hair loss treatments discussed include 200mg Spiro, bicalutamide, and finasteride. Endocrinologist advises against bicalutamide and finasteride due to potency and risks.

      community 2.5 years Minoxidil and HRT, CPA->Lupron +Minox 5%

      in Transgender  611 upvotes 1 year ago
      The user experienced significant hair regrowth after 2.5 years of using Minoxidil 5% and hormone replacement therapy (HRT) with Lupron, despite initial scalp irritation. Finasteride was ineffective for them.

      community Im on 2.5 mg dutasteride, RU, 15 mg Oral Minoxidil, 300 mg Isoflavones, 1800mg NAC, 1000mg Pumpkin Seed Oil, NAD+ and Vipelin

      in Finasteride/Dutasteride  20 upvotes 3 years ago
      The user improved their hair loss from a Norwood scale 2.5/3 to 1.5/2 using treatments including 2.5 mg dutasteride, RU58841, 15 mg oral minoxidil, isoflavones, NAC, pumpkin seed oil, NAD+, and Vipelin, but still experiences temple recession. Other users expressed concern over the high dosages of oral minoxidil and dutasteride.

      community Is this solution unnecessarily aggresive?

      in Product  2 upvotes 6 months ago
      The solution contains minoxidil, finasteride, azelaic acid, caffeine, retinoic acid, and procapil. Users suggest minoxidil with tretinoin and a 5-alpha reductase inhibitor, while dismissing retinoic and azelaic acids as unnecessary.

      community Do you think clascoterone is overhyped

      in Treatment  14 upvotes 1 month ago
      Clascoterone is considered overhyped and not as effective as finasteride or dutasteride, but it may be useful as a supportive treatment in combination with other therapies. Users express skepticism about its effectiveness compared to clinical trials, with some suggesting it could be beneficial for those who cannot tolerate other treatments.

      community I hope ET-02 or PP405 will be released in the next 4-5 years

      in Product  15 upvotes 1 year ago
      PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

      community SCUBE 3 (the last hair bender)

      in Research/Science  2 upvotes 11 months ago
      SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

      community Ben Greenfield Podcast : CHK-Cu & C-60

      in Research/Science  5 upvotes 5 years ago
      CHK-Cu (copper peptide) and C-60 (branched carbon chain) are discussed as potentially more effective than minoxidil for hair regrowth. Some users are skeptical about the claim that DHT isn't the root cause of hair loss, and others are trying these products to see if they work.

      community 4 month is in - 2 pics - fin/min+

      in Progress Pictures  386 upvotes 1 year ago
      The user shared a 4-month update on their hair regrowth journey using finasteride, minoxidil, and microneedling, reporting significant progress and styling ability. They emphasized persistence, shared their regimen details, and addressed side effects like weaker erections and blurry vision, which improved with lifestyle changes.

      community Disappointing news on Breezula/CB-03-01

       22 upvotes 7 years ago
      The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

      community Musely s Exosome formulation looks interesting

      in Chat  13 upvotes 1 year ago
      Exosomes, cetirizine, melatonin, latanoprost, and caffeine are discussed as potential hair loss treatments. There is skepticism about the effectiveness of exosomes, especially in topical form, but some users report positive results.

      community Breezula Phase 3 Results enough for maintenance?

      in Treatment  11 upvotes 2 months ago
      Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.